TRAX
First Tracks Biotherapeutics Inc
NASDAQ · Healthcare · Biotechnology · US
$40.46
−4.82%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +0.1%
- EBIT
- +1.2%
- Net income
- -1.5%
- EPS
- —
- Free cash flow
- -13.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026